Table 3.
Medication prescribed in early COPD
| 2007 (n=110) | 2008 (n=139) | 2009 (n=126) | 2010 (n=159) | 2011 (n=170) | 2012 (n=179) | |
|---|---|---|---|---|---|---|
| ICS, n (%) | 7 (6.4) | 5 (3.6) | 10 (7.9) | 8 (5.0) | 7 (4.1) | 15 (8.4) |
| ICS + LABA, n (%) | 17 (15.5) | 24 (17.3) | 25 (19.8) | 29 (18.2) | 42 (24.7) | 44 (24.6) |
| LAMA, n (%) | 12 (10.9) | 18 (12.9) | 18 (14.3) | 30 (18.9) | 37 (21.8) | 44 (24.6) |
| SAMA, n (%) | 12 (10.9) | 6 (4.3) | 10 (7.9) | 11 (6.9) | 9 (5.3) | 13 (7.3) |
| SABA, n (%) | 20 (18.2) | 18 (12.9) | 18 (14.3) | 26 (16.4) | 25 (14.7) | 44 (24.6) |
| Systemic bronchodilator, n (%) | 41 (37.3) | 41 (29.5) | 43 (34.1) | 41 (25.8) | 43 (25.3) | 43 (24.0) |
| Methylxanthine, n (%) | 63 (57.3) | 73 (52.5) | 71 (56.3) | 82 (51.6) | 79 (46.5) | 92 (51.4) |
Abbreviations: ICS, inhaled corticosteroid; ICS + LABA, inhaled corticosteroid plus long-acting beta-2 agonist; LAMA, long-acting muscarinic antagonist; SAMA, short-acting muscarinic antagonist; SABA, short-acting beta-2 agonist.